Aviragen Therapeutics (AVIR) Reports Q4 Loss of $0.15/Share

Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.15), versus ($0.18) reported last year.

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• TaiMed Biologics gets TFDA drug license notice for HIV therapy Trogarzo
• Raymond James Upgrades Dollar Tree (DLTR) to Outperform